SIAP
ALXN

Sterling Investment Advisors (Pennsylvania)’s Alexion Pharmaceuticals ALXN Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2
Closed – – 621
2021
Q2 		$0 Hold
2
– – ﹤0.01% 587
2021
Q1 		$0 Hold
2
– – ﹤0.01% 550
2020
Q4 		$0 Hold
2
– – ﹤0.01% 488
2020
Q3 		$0 Hold
2
– – ﹤0.01% 475
2020
Q2 		$0 Hold
2
– – ﹤0.01% 455
2020
Q1 		$0 Hold
2
– – ﹤0.01% 461
2019
Q4 		$0 Hold
2
– – ﹤0.01% 456
2019
Q3 		$0 Buy
+2
New +$225 ﹤0.01% 455

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s ALXN Position: Q3 2021 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2 shares.

Sterling Investment Advisors (Pennsylvania) first reported a position in ALXN in Q3 2019 and held it in 8 quarters. The position peaked at $0 in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Sterling Investment Advisors (Pennsylvania) reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Sterling Investment Advisors (Pennsylvania) sold 2 Alexion Pharmaceuticals shares in Q3 2021.
  • Sterling Investment Advisors (Pennsylvania) first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 8 quarters.
  • Sterling Investment Advisors (Pennsylvania)'s Alexion Pharmaceuticals position peaked at $0 in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2021, filed 9 Nov 2021.